Tokyo Japan - Institute of Medicinal Molecular Design, Inc. (IMMD) today announced that it has successfully completed the phase I clinical trial of topical formulation of IMD-0354, a small molecule compound having been developed by IMMD for treatment of atopic dermatitis, and confirmed its safety profile as a novel drug candidate for further development.
